Get the Stockscreener App
111.68
5.41%
5.775
Belite Bio Inc Adr stock is traded at $111.68, with a volume of 120.60K.
It is up +5.41% in the last 24 hours and up +47.66% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$105.91
Open:
$107.5
24h Volume:
120.60K
Relative Volume:
1.99
Market Cap:
$3.56B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-95.11
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
+18.99%
1M Performance:
+47.66%
6M Performance:
+78.16%
1Y Performance:
+59.70%
1-Day Range:
$107.00
$115.41
1-Week Range:
$90.77
$115.41
52-Week Range:
$49.00
$115.41
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
111.86 | 3.70B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio (NASDAQ: BLTE) to host third-quarter results webcast at 4:30 p.m. ET - Stock Titan
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of... - markets.businessinsider.com
Belite Bio Announces UK’s Medicines and Healthcare Products - GlobeNewswire
Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat
Belite Bio stock hits all-time high at 101.92 USD By Investing.com - Investing.com Australia
Belite Bio stock hits all-time high at 101.92 USD - Investing.com
Can machine learning forecast Belite Bio Inc Depositary Receipt recoveryIndex Update & Consistent Growth Equity Picks - newser.com
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
How Belite Bio Inc Depositary Receipt stock performs during Fed tightening cyclesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Belite Bio to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference November 4th - GlobeNewswire
Belite Bio (NASDAQ: BLTE) to present 10:30 ET at ADR Virtual Investor Conf.; 90-day replay - Stock Titan
How Belite Bio Inc (Common Stock) (D01) stock valuation compares with sectorJuly 2025 Update & Reliable Entry Point Trade Alerts - fcp.pa.gov.br
Risk vs reward if holding onto Belite Bio Inc Depositary ReceiptJuly 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Why Belite Bio Inc Depositary Receipt stock could benefit from AI revolution2025 Sector Review & Daily Oversold Bounce Ideas - newser.com
Belite Bio (NASDAQ:BLTE) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Will Belite Bio Inc (Common Stock) (D01) stock outperform energy sector in 2025Earnings Trend Report & Stepwise Entry and Exit Trade Signals - newser.com
Belite Bio stock reaches all-time high at 92.12 USD By Investing.com - Investing.com Nigeria
Belite Bio stock reaches all-time high at 92.12 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Sets New 52-Week High – Should You Buy? - Defense World
Is Belite Bio Inc Depositary Receipt stock a safe investment in uncertain markets2025 Market WrapUp & Technical Pattern Based Buy Signals - nchmf.gov.vn
Belite Bio stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Belite Bio (NASDAQ:BLTE) Trading Up 6.7%Should You Buy? - MarketBeat
(BLTE) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Belite Bio stock hits all-time high at 86.61 USD By Investing.com - Investing.com Philippines
Belite Bio to Participate in the 2025 Maxim Growth Summit - markets.businessinsider.com
Belite Bio stock hits all-time high at 86.61 USD - Investing.com
Belite Bio Stocks Surge Amid Drug Approval Hopes - TipRanks
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $96.00 Consensus Target Price from Brokerages - Defense World
Eagle Point Credit Company Inc. (NYSE:ECC) Receives $8.21 Average Price Target from Analysts - Defense World
Oct. 22, 2025: Belite Bio to Participate in Maxim Growth Summit; meetings available via Maxim rep - Stock Titan
Phase 3 interim prompts China NMPA Priority NDA Review — Belite Bio's Tinlarebant; topline Q4 2025 - Stock Titan
Cango Inc. to Terminate ADR Program and List Class A Ordinary Shares Directly on NYSE - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - Yahoo Finance
Benchmark Co. Reaffirms Their Buy Rating on Biofrontera (BFRI) - The Globe and Mail
What MACD signals say about Belite Bio Inc Depositary Receipt2025 Top Gainers & Real-Time Market Trend Scan - newser.com
GAMMA Investing LLC Trims Stock Holdings in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com
3 Lesser-Known Healthcare Names With Major Upside in Store - MarketBeat
Volume spikes in Belite Bio Inc Depositary Receipt stock – what they mean2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Juvenile Macular Degeneration Pipeline 2025: Innovative Clinical Developments by 80+ Global Leaders – DelveInsight | Highlighting Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen - Barchart.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeHere's Why - MarketBeat
Belite Bio (NASDAQ:BLTE) Upgraded at Wall Street Zen - MarketBeat
Stargardt Disease Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Belite Bio (NASDAQ:BLTE) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
Analysts Set Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) PT at $96.00 - MarketBeat
HC Wainwright Has Positive Outlook of Belite Bio Q3 Earnings - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $96.00 Average Target Price from Analysts - Defense World
Lin BioScience Subsidiary Belite Completes LBS-008 STGD1 Phase III Trial, Secures NT$8.4 Billion Private Placement - 全球醫療採購網
HC Wainwright Has Lowered Expectations for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):